SOST

SOST 詳細

英語名Sclerostin市販薬剤の数1
治験薬の数6ターゲットの別称Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
研究&開発段階Approved
英語名Sclerostin
ターゲットの別称Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
市販薬剤の数1
治験薬の数6
研究&開発段階Approved

SOST 製品リスト

  • 属性

    Protein (4)

  • 製品ライブラリ

    オンライン (4)

  • 種

    Human (2)Mouse (2)

  • タグ

    His Tag (3)His Tag & Avi Tag (1)

  • マーカー

    Unconjugated (2)Biotin-labeled (2)

SOSTバックグランド

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST分子の別称

SOST,VBCH

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
SetrusumabUX143; NOV-3; MOR-05813; BPS-804Phase 3 ClinicalMorphosys Ag, Novartis Pharma AgBone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic
詳細
AGA-2115AGA2115; AGA-2115Phase 2 ClinicalAngitia Biopharmaceuticals (Guangzhou) LtdOsteogenesis Imperfecta
詳細
AGA-2118AGA-2118Phase 2 ClinicalAngitia Biomedicines LtdOsteoporosis; Osteoporosis, Postmenopausal
詳細
ResugosbartSHR-1222Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co LtdOsteoporosis; Osteoporosis, Postmenopausal
詳細
Romosozumab biosimilar(Zhuhai Federation Biomedicine)Phase 1 ClinicalZhuhai Federation Biomedicine Co LtdOsteoporosis, Postmenopausal
詳細
BlosozumabTST002; LY-2541546; TST002-IgG4Phase 1 ClinicalEli Lilly And CompanyOsteoporosis; Osteoporosis, Postmenopausal
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
RomosozumabCDP-7851; AMG-785ApprovedEvenity, EVENITYJapanOsteoporosisAmgen Inc2019-01-08Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal
詳細
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報